Welcome to our dedicated page for GE HealthCare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GE HealthCare Technologies Inc. filings document formal disclosures for a medical technology and diagnostics company, including Form 8-K reports on results of operations and financial condition, material agreements, capital-structure matters, and governance changes. Recent current reports include earnings releases, a senior unsecured revolving credit facility, and board-related disclosures.
The company’s proxy materials describe annual-meeting matters, director elections, board committee assignments, executive compensation, equity awards, and shareholder voting procedures. GEHC filings also provide formal context for segment performance, liquidity arrangements, credit covenants, and governance matters tied to its healthcare technology, software, and pharmaceutical diagnostics businesses.
GE HealthCare Technologies Inc. director William J. Stromberg reported a compensation-related equity grant. On May 7, 2026, he acquired 3,586 restricted stock units (RSUs), each representing one future share of common stock. These RSUs vest 100% on the earlier of the company’s next annual stockholder meeting or May 7, 2027. Stromberg can elect to defer settlement under GE HealthCare’s Non-Employee Director Compensation and Benefits Plan, meaning the actual delivery of shares can occur later according to his deferral election. Following this award, his direct holdings reported in this filing total 18,916 shares of common stock.
GE HealthCare Technologies Inc. held its annual stockholder meeting on May 7, 2026, where eight directors were elected to one-year terms. Vote totals for each nominee were strong, with Peter J. Arduini receiving 363,637,737 votes for and H. Lawrence Culp, Jr. receiving 351,620,004 votes for.
Stockholders approved the advisory vote on named executive officer compensation with 351,099,781 votes for and 12,973,200 against. They also ratified Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026, with 398,257,878 votes for and 769,608 against.
Effective May 7, 2026, the Board appointed Rodney F. Hochman as independent lead director and named Anne T. Madden as chairperson of the Nominating and Governance Committee, signaling updated leadership roles within the board structure.
GE HealthCare Technologies director H. Lawrence Culp Jr. reported an open-market purchase of 80,805 shares of common stock at a weighted average price of $61.8783 per share, with individual trades between $61.50 and $62.22. Following this transaction, he indirectly holds 151,207 shares through a holding company, 328,268 shares through family trusts, and 12,699 shares directly.
GE HealthCare Technologies Inc. director William J. Stromberg reported an open-market purchase of company stock. On May 6, 2026, he bought 1,000 shares of common stock at $61.6892 per share, bringing his directly held ownership to 15,330 shares after the transaction.
GE HealthCare Technologies Inc. executive Catherine Estrampes, Chief Commercial & Growth Officer, reports beneficial ownership of 24,081 shares of common stock. This includes 14,374 shares plus restricted stock units that may settle into additional shares as they vest.
She also holds multiple employee stock options on GE HealthCare common stock. These options cover underlying share amounts such as 16,398 shares at an exercise price of $80.16 expiring on March 2, 2036, and 9,923 shares at $86.45 expiring on March 3, 2035, along with several other grants with different prices and expirations.
GE HealthCare Technologies Inc. Chief Financial Officer James Saccaro purchased 3,310 shares of Common Stock in an open-market transaction on May 1, 2026 at a weighted average price of $60.5997 per share. Following this purchase, he directly owns 87,471 shares. The filing notes the shares were bought in multiple trades at prices ranging from $60.59 to $60.60 per share.
GE HealthCare Technologies Inc. General Counsel and Corporate Secretary Frank R. Jimenez reported an open-market purchase of 1,750 shares of common stock at a price of $60.45 per share. Following this transaction, he directly owns 93,932 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc. President and CEO Peter J. Arduini made an open-market purchase of company stock. On this date, he bought 4,169 shares of common stock at $59.925 per share.
After this transaction, Arduini directly owns 259,424 shares of GE HealthCare common stock. This filing shows a net increase in his personal shareholding through a straightforward open-market purchase.
GE HealthCare Technologies Inc reported that Vanguard Capital Management beneficially owned 33,370,111 shares of common stock, representing 7.31% of the class as of 03/31/2026. The filing shows sole voting power for 4,505,923 shares and sole dispositive power for 33,370,111 shares, and includes a disclosure that ownership reflects holdings of Vanguard affiliates and managed funds.
GE HealthCare Technologies reported first‑quarter 2026 revenue of $5.13 billion, up from $4.78 billion a year earlier, driven by higher product and service sales across segments. Net income attributable to GE HealthCare fell to $389 million from $564 million as operating income declined to $515 million from $629 million, pressured in part by restructuring, acquisition‑related costs, and higher tariffs.
The company closed the $2.30 billion cash acquisition of Intelerad, adding significant imaging software capabilities and increasing goodwill and definite‑lived intangibles. Operating cash flow was $290 million, while investing activities used $2.50 billion, largely for Intelerad. GE HealthCare also repurchased $100 million of stock and ended the quarter with $2.29 billion in cash and $10.13 billion of borrowings.